KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Astrazeneca (AZN) Total Current Liabilities (2016 - 2025)

Astrazeneca (AZN) has 3 years of Total Current Liabilities data on record, last reported at $30.6 billion in Q4 2025.

  • For Q4 2025, Total Current Liabilities rose 9.87% year-over-year to $30.6 billion; the TTM value through Dec 2025 reached $30.6 billion, up 9.87%, while the annual FY2025 figure was $30.6 billion, 9.87% up from the prior year.
  • Total Current Liabilities reached $30.6 billion in Q4 2025 per AZN's latest filing, up from $27.9 billion in the prior quarter.
  • Across five years, Total Current Liabilities topped out at $30.6 billion in Q4 2025 and bottomed at $27.9 billion in Q4 2024.
  • Average Total Current Liabilities over 3 years is $29.7 billion, with a median of $30.5 billion recorded in 2023.
  • Peak YoY movement for Total Current Liabilities: fell 8.76% in 2024, then increased 9.87% in 2025.
  • A 3-year view of Total Current Liabilities shows it stood at $30.5 billion in 2023, then decreased by 8.76% to $27.9 billion in 2024, then increased by 9.87% to $30.6 billion in 2025.
  • Per Business Quant database, its latest 3 readings for Total Current Liabilities were $30.6 billion in Q4 2025, $27.9 billion in Q4 2024, and $30.5 billion in Q4 2023.